Previously reported findings have indicated that circulating methylated TMEM240 levels gradually decrease in Taiwanese patients with nonprogressive breast cancer and increase in those with disease progression, demonstrating a remarkable predictive accuracy of 96.1%. Here, TMEM240 is linked to breast carcinoma.